Cancer care is undergoing a quiet revolution, and it's happening right in your backyard. More than half of U.S. cancer patients now receive treatment in community settings, a dramatic shift that's reshaping the landscape of oncology. But here's where it gets controversial: as diagnoses become more precise and patients live longer with cancer, is community-based care truly equipped to handle the complexities of modern treatment? In a recent episode of The Top Line, Kirk Kaminsky, Executive Vice President and Group President of North American Pharmaceutical Services at McKesson, dives into this very question. He argues that community oncology has become a cornerstone of modern cancer care, offering patients the convenience of treatment closer to home while easing the burden on the healthcare system.
Kaminsky highlights how the rapid pace of innovation is transforming community practices, but it’s not without challenges. New demands in reimbursement and operations are putting pressure on providers, raising the question: can smaller practices keep up? This is the part most people miss—McKesson and The US Oncology Network are stepping in to bridge the gap, providing technology, administrative support, and patient-focused resources. The goal? To let oncologists focus on what they do best: delivering care, not managing complexity.
But the story doesn’t end there. Community oncology is also playing a growing role in clinical trials, bringing cutting-edge treatments to local patients who might otherwise be excluded. And with artificial intelligence streamlining workflows and reducing administrative burdens, the potential for efficiency is staggering. Yet, this raises another provocative question: as AI becomes more integrated, will it enhance or replace the human touch in patient care?
Kaminsky’s insights paint a compelling picture of the future of cancer care, but they also leave us with a critical debate: Is the shift to community oncology a sustainable solution, or does it risk overextending local resources? Listen to the full interview to hear his perspective, and let us know—do you think community oncology is the future, or are there pitfalls we’re overlooking? The conversation is just beginning.
